8 rezultatov
FIELD
The present invention relates to compounds by the regulation of cannabinoid receptors. More specifically, the compounds are inverse antagonists of cannabinoid receptor subtype-2, otherwise known as CB2.
BACKGROUND
Osteoporosis is a major metabolic bone disease that affects 44 million Americans
FIELD
The present invention relates to compounds by the regulation of cannabinoid receptors. More specifically, the compounds are inverse antagonists of cannabinoid receptor subtype-2, otherwise known as CB2.
BACKGROUND
Osteoporosis is a major metabolic bone disease that affects 44 million Americans
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Stage Application under 35 U.S.C. .sctn.371 of International Application No. PCT/US2010/002360, filed Aug. 27, 2010, which claims priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application Nos. 61/275,506, filed Aug.
FIELD OF THE INVENTION
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB.sub.2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions
BACKGROUND
The field of cannabinoid research has gained attention in recent years, particularly in view of the legal use of medical marijuana now approved in several states. However, medical marijuana or cannabinoid (CB) has reached certain limitation. Cannabinoid (CB) drug research also faces a
The present disclosure relates to the fields of pharmaceutical and organic chemistry, and provides 4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB.sub.1 receptor modulators, intermediates for synthesizing these compounds, formulations comprising these compounds, methods for
FIELD OF THE INVENTION
The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclop- ropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that
FIELD OF THE INVENTION
The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclop- ropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that